A recently published Chinese trial of sorafenib in advanced NSCLC who progressed on EGFR TKI indicated that sorafenib did not improve survival (PFS: 3.7months; OS: 7.4 months). This evidence concerns the gene EGFR and non-small cell lung carcinoma.